Introduction
============

Due to the development of screening programs, the incidence of cervical cancer has decreased worldwide; however, the incidence of cervical adenocarcinoma (CA) has increased, especially in younger age groups. According to the literature, cervical cancer is the fourth most frequently occurring malignancy among women and the second most common malignancy of the female genital tract, with 200,000 deaths and 500,000 new cases worldwide annually.[@b1-cmar-10-6029],[@b2-cmar-10-6029] CA histopathology accounts for 5%--25% of all cervical cancer cases. Data on the influence of histopathology on survival in cancer patients are conflicting; however, most studies confirm adenocarcinoma histopathology as a poor prognostic factor in cervical cancer.[@b3-cmar-10-6029]--[@b5-cmar-10-6029] Some authors have identified different molecular profiles between histopathological types and the need for clinical trials to determine the optimal treatment regimen to enhance the outcome of patients with CA.[@b4-cmar-10-6029]--[@b7-cmar-10-6029] Cervical cancer is staged according to International Federation of Gynecology and Obstetrics (FIGO) classification. The clinical stage of the disease can be assessed clinically but other parameters are assessed surgically. Therefore, non-invasive pretreatment parameters, which can be used conveniently and cost-effectively, are needed to predict the clinical course of the disease and the likelihood of response to treatment. Serum C-reactive protein (CRP) is not routinely evaluated before treatment, and it has been shown to have a negative prognostic value in patients with other malignancies such as hepatocellular cancer[@b8-cmar-10-6029] and ovarian carcinoma.[@b9-cmar-10-6029] The inflammation process plays an important role in the carcinogenesis and cancer progression and may act as a measure of disease progression. Neutrophils have been shown to secrete vascular endothelial growth factor, IL-18, and matrix metalloproteinases that directly contribute to tumor-related angiogenesis, tumor growth, and metastatic processes.[@b10-cmar-10-6029]--[@b12-cmar-10-6029] Systemic nonspecific markers of inflammation such as the platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) have been investigated in different types of malignancies such as non-small-cell lung cancer,[@b13-cmar-10-6029] pancreatic cancer,[@b14-cmar-10-6029] gastric cancer,[@b15-cmar-10-6029],[@b16-cmar-10-6029] renal cell,[@b17-cmar-10-6029] and colorectal cancer.[@b18-cmar-10-6029]--[@b20-cmar-10-6029] Several studies have also evaluated the role of systemic inflammation in malignancy in cervical cancer. However, little is known about the prognostic value of the pretreatment levels of inflammatory markers, including white blood cell count (WBC), NLR, and PLR, in patients with CA. To our knowledge, there are no studies on the role of these parameters in this histopathological type of cervical carcinoma. Taking into account that adenocarcinoma often presents with less favorable outcomes,[@b3-cmar-10-6029]--[@b5-cmar-10-6029],[@b21-cmar-10-6029] the assessment of easily applicable prognostic factors for possible additional therapies is of particular importance.

The aim of this study was to determine the clinical usefulness and prognostic value of pretreatment hematological parameters including WBC, hemoglobin (Hb), and platelets (PLT) as well as calculated coefficients such as NLR, PLR, and monocyte to lymphocyte ratio (MLR) in patients with CA.

Materials and methods
=====================

We retrospectively analyzed data from cervical cancer patients with FIGO stage IA--IV disease who were treated consecutively from November 2003 to January 2008 at the Maria Sklodowska-Curie Institute-Oncology Center in War-saw. The eligibility criteria included patients with cervical cancer with confirmed adenocarcinoma histopathology who were qualified to receive radical treatment. The histopathological features of all tumors were confirmed by our institutional pathologist. Data on all clinical factors and complete blood parameters were collected within 10 days before treatment. Blood samples were evaluated using a Sysmex XN-2000 system. The NLR was defined as the absolute number of neutrophils divided by the absolute number of lymphocytes (G/L), the PLR as the absolute number of PLT by the absolute number of lymphocytes (G/L), and the MLR as the absolute number of monocytes by the absolute number of lymphocytes (G/L) in patients with adenocarcinoma of the uterine cervix. Patients were staged according to FIGO classification and treated according to European Society for Medical Oncology and European Society of Radiotherapy and Oncology (ESTRO) recommendations. Before treatment, patients were staged with clinical examination, computed tomography (CT) or X-ray imaging of the chest, and CT or magnetic resonance (MR) of the abdomen and pelvis. In case of suspected infiltration of the bladder or rectum, histopathological confirmation of cystoscopy or rectoscopy specimens was performed. Patients with early cervical cancer (FIGO stages IA 1--2, IB1, and IIA) were treated with radical hysterectomy and bilateral oophorectomy, including the part of the cardinal and uterosacral ligament at the upper end of the vagina, as well as pelvic lymphadenectomy. In case of enlarged para-aortal lymph nodes, para-aortal lymphadenectomy or biopsy was performed. After surgical treatment, patients were qualified for adjuvant therapy based on risk factors. In case of the presence of at least two intermediate risk factors such as deep stromal invasion, large tumor, or lymphovascular space invasion, the patients were administered external beam irradiation (EBRT) with or without chemotherapy and brachytherapy (BT) as two 7.5-Gray (Gy) fractions prescribed to the vaginal vault. Patients with high-risk factors such as positive lymph nodes (N1), positive margins (R1), or parametrial infiltration were treated with chemoradiotherapy (CCRT). Patients with locally advanced cervical cancer, FIGO stages IB2, IIB--IVA, were also treated with CCRT. The first-line therapy in these patients included CCRT with weekly cisplatin at a dose of 40 mg/m^2^ of body surface area. Patients qualified to receive CCRT were treated with EBRT to the pelvis, and sometimes, to the para-aortic area, based on the three-dimensional (3D) planning system calculated using a HELAX system, according to the recommendations of Reports 50 and 62 of the International Commission on Radiation Units and Measurements (ICRU) with a 3D conformal technique. Clinical target volumes (CTVs) with a margin of 5 mm in all directions were delineated on the CT scans, and the planning target volumes (PTVs) were defined. Organs at risk (OAR) were also delineated during the planning procedure. Patients were treated with a total dose of 45--46 Gy to the pelvic and/or para-aortal region, and a 60--64 Gy boost in cases of enlarged lymph nodes measuring over 2 cm or resistant tumor in the parametrium. The patients started high-dose rate (HDR) BT in 1--3 weeks after EBRT. BT was performed with an iridium (Ir-192) source from microSelectron^®^ (Nucletron Devices) once a week with 4 fractions of 7.5 Gy for a total dose of 30 Gy prescribed to the high-risk CTV. BT was planned according to the Groupe Européen de Curiethérapie-ESTRO recommendations with wider margins in the uterus and vaginal directions due to the lack of MR-based planning possibilities, according to the ICRU 38 Report. The planning system was based on CT images or radiographs. During the planning procedure, the PTV and OAR were delineated on CT scans. Fletcher, ring applicator, or 2--6 interstitial metal needles and intrauterine catheters were used to perform the HDR-BT.

The patients were followed-up every 3 months for the first 2 years, at 6-month intervals for the next 3, and annually after 5 years. In case of suspected relapse, we obtained histologically evaluated biopsy specimens. Patient follow-up was maintained until death or last observation, with a cutoff date of December 31, 2017.

Nonparametric Mann--Whitney *U*-tests were used for statistical comparisons of two independent groups. The probabilities of recurrence-free survival (RFS) and overall survival (OS) were assessed using univariate analysis with log-rank tests and multivariate analysis using Cox proportional hazards models. The OS was defined as the time interval between the start of treatment and the last follow-up or death. The RFS was the period between the first day of the treatment and disease recurrence, local or distant. The level of significance was *P*\<0.05. The cutoff points for the calculated hematological coefficients (NLR, PLR, and MLR) were determined using the MedCalc statistical program.

Results
=======

Among 738 patients with cervical cancer treated at our center, we excluded those with squamous cell histopathology (642) and two CA patients treated with palliative intent and included all patients with CA who were qualified to receive radical treatment; thus, a total of 94 patients with CA were included in the final analysis. Their median age was 53 years (range: 20--81 years). Forty-two patients had early-stage disease (FIGO I--IIA) and 52 had advanced disease (FIGO IIB--IVA). Early-stage disease was confirmed in 37 (61%) premenopausal and 57 (35%) postmenopausal patients. During the long-term follow-up (median: 66 months; range: 4.6--171.4 months), disease recurrence was observed in 44 (49%) patients (median age: 54 years), including 15 premenopausal and 29 postmenopausal women. The median time to relapse was 25 months. Forty-eight (51%) patients died. The clinical and pathological features of the patients with CA, the treatment characteristics, and the outcomes are presented in [Table 1](#t1-cmar-10-6029){ref-type="table"}.

NLR, PLR, and MLR and the ranges of the absolute numbers and median hematological parameters
--------------------------------------------------------------------------------------------

The median pretreatment NLR was 2.32 (range: 0.7--20.3). The median PLR was 158 (range: 62.6--634). The calculated coefficients of NLR, PLR, and MLR, the ranges of the absolute numbers, and medians of the hematological parameters (Hb, WBC, and PLT) overall according to FIGO and clinical conditions are presented in [Table 2](#t2-cmar-10-6029){ref-type="table"}.

We next evaluated the correlation between the examined parameters and the age of patients, FIGO stage, and clinical status during the follow-up. No statistically significant correlations between age (\<50 vs \>50 years), FIGO stage, and the values of the studied parameters were observed. In patients with FIGO IIB--IV disease, only a trend of elevated NLR was observed (*P*=0.06). Of all hematological parameters, pretreatment WBC (*P*=0.009) was significantly higher in patients who died during follow-up than in patients who survived, as analyzed using the Mann--Whitney *U*-test ([Figure 1](#f1-cmar-10-6029){ref-type="fig"}). Higher WBC values were also demonstrated in patients with metastases compared to the nonmetastatic group, however, this relationship was observed to be a trend (*P*=0.054).

Based on the analysis of receiver operating characteristic (ROC) curves for hematological factors cutoff points for NLR, PLR, and MLR were determined while maintaining the optimal sensitivity and specificity of tests for recurrence and no-recurrence groups. The results are presented in [Table 3](#t3-cmar-10-6029){ref-type="table"}.

Next, we analyzed the prognostic value of the examined parameters for RFS and OS. The first group comprised of patients treated with surgery and BT, EBRT, or CCRT (n=47); and the second group included patients treated with radiotherapy (RT) alone or CCRT (n=47).

The influence of the examined parameters on RFS in the whole group of patients
------------------------------------------------------------------------------

The results of the log-rank univariate analysis demonstrated that disease stage (FIGO IIB--IV) (*P*=0.002) and conservative treatment modality (patients treated only with RT or CCRT) (*P*=0.004) were associated with a shorter time to relapse. Among the hematological coefficients, NLR tended to be associated with RFS (*P*=0.059). However, multivariate Cox analysis demonstrated that the rate of NLR (*P*=0.021; HR 3.0; 95% CI: 2.063--3.936) was an independent prognostic factor and elevated values were associated with a worse RFS ([Figure 2A](#f2-cmar-10-6029){ref-type="fig"}). In the group of patients treated with surgery and further BT, RT, or CCRT (n=47), the correlation between NLR (*P*=0.001), PLR (*P*=0.006), and Hb (*P*=0.01) with RFS was demonstrated in log-rank tests, while Cox analysis revealed that only elevated NLR (*P*=0.049; HR: 4.0; 95% CI: 2.612--5.392) was an independent and poor prognostic factor for RFS ([Figure 2B](#f2-cmar-10-6029){ref-type="fig"}).

The prognostic value of the examined parameters on OS in the whole group of patients
------------------------------------------------------------------------------------

OS was associated with disease stage (FIGO IIB--IV) (*P*=0.0001) and conservative treatment modality, which is the treatment of choice for this clinical stage. Patients treated with RT or CCRT only (*P*=0.004) had a shorter OS, which may also be an effect of the disease advancement. Cox multivariate analysis revealed that, among hematological parameters, an elevated NLR was a poor prognostic factor for OS (*P*=0.014; HR: 2.85; 95% CI: 2.011--3.685) ([Figure 3](#f3-cmar-10-6029){ref-type="fig"}).

Survival analysis in patient groups divided according to FIGO stage and treatment modality confirmed that elevated values of PLR were correlated with poor prognosis for OS in patients with FIGO stage IIB-IV treated with RT/CCRT (*P*=0.017; HR: 2.96; 95% CI: 2.069--3.853) ([Figure 4](#f4-cmar-10-6029){ref-type="fig"}).

Discussion
==========

To our knowledge, this is the first study with mature data to investigate the prognostic value of pretreatment NLR, PLR, and other hematological parameters in patients with CA. As this histopathological type generally has a less favorable outcome,[@b21-cmar-10-6029],[@b22-cmar-10-6029] easy and inexpensive identification of high-risk groups is especially important. Therefore, selecting patients with a particularly unfavorable prognosis and encouraging them to consider the use of new forms of treatment is a priority task. This study is a continuation of a material analysis of tumor markers.[@b23-cmar-10-6029] Further analyses were performed to identify low-cost and widely available data on hematological parameters in this group of patients.

The NLR may act as a marker for the evaluation of the systemic balance between pro-tumor inflammation associated with neutrophils and antitumor immune response associated with lymphocytes. An increased NLR may indicate a trend for decreased antitumor immune capacity and increased pro-tumor inflammation.[@b24-cmar-10-6029] In another study,[@b25-cmar-10-6029] a higher NLR was associated with more advanced disease stage in younger patients. More advanced disease stage and elevated pretreatment NLR in patients with CA in our study were significantly associated with poorer RFS and OS. This finding is in accordance with previous studies reporting that the pretreatment NLR is associated with survival in patients with other malignancies as well as cervical cancer, especially those with advanced disease.[@b26-cmar-10-6029],[@b27-cmar-10-6029] Zhang et al demonstrated the poor prognostic influence of NLR on RFS, but not OS, in cervical carcinoma patients treated with surgery. They found that an elevated NLR was associated with lymph node metastases (LNM) and the depth of stromal infiltration.[@b28-cmar-10-6029] In patients with cervical squamous cell carcinoma treated with CCRT, NLR was a highly significant prognostic factor for RFS and OS. Moreover, a low NLR was significantly associated with a complete response to treatment with CCRT.[@b29-cmar-10-6029] In an analysis by Huang et al, a high pretreatment NLR was an adverse prognostic factor for OS and RFS and was also significantly associated with FIGO stage, LNM, and tumor size.[@b30-cmar-10-6029] The prognostic value of pretreatment NLR was confirmed in a study of patients with a wide range of malignancies.[@b31-cmar-10-6029] In a study of cervical cancer treated with RT, Cho et al reported that an increased NLR was associated with a poorer treatment response and more aggressive disease.[@b32-cmar-10-6029]

Our results also confirmed that more advanced FIGO stage and elevated NLR were significantly associated with a poorer outcome. Wang et al did not confirm the predictive values of NLR and PLR in cervical cancer patients treated with neoadjuvant chemotherapy and surgery.[@b33-cmar-10-6029] However, our study did not include these patients.

Besides low lymphocyte values, thrombocytosis has also been reported as a marker of host systemic inflammation. Its prognostic value in malignancies has been confirmed.[@b34-cmar-10-6029]--[@b37-cmar-10-6029] Pretreatment peripheral PLR has been shown to have prognostic value for LNM and clinical outcome in early cervical cancer treated with surgery.[@b38-cmar-10-6029] According to Nakamura et al, the pretreatment PLR may be an independent predictor of recurrence in cervical cancer patients treated with CCRT.[@b39-cmar-10-6029] The findings of our study demonstrated that pretreatment PLR was significantly correlated with the prognosis of CA patients treated with RT/CCRT. Elevated pretreatment PLR in patients with FIGO stage IIB--IV disease treated with RT/CCRT negatively impacted the OS. Once confirmed in a larger study group, these results have significant potential for wider application in practice. Considering that CA histology has been reported to be a poor prognostic factor for worse response to CCRT, this is a unique information with regard to this group of patients. Therefore, it seems reasonable to consider whether this particular group should not be subjected to complementary treatments such as targeted therapy or the addition of anti-inflammatory agents.

Leukocytes, being at the center of the inflammatory response to tumor formation, have been the subject of evaluation in many studies on colorectal and lung cancers.[@b12-cmar-10-6029],[@b40-cmar-10-6029] The results of our study demonstrated that elevated pretreatment values of WBC in patients with cervical carcinoma were related to a shorter OS. The findings of other study confirmed that WBC may predict survival in these patients. The prognostic value of WBC in cervical cancer has been demonstrated in other studies.[@b25-cmar-10-6029],[@b34-cmar-10-6029],[@b41-cmar-10-6029] The total WBC may be a significant addition to the other established markers of systemic inflammation, including albumin, CRP, lymphocytes counts, neutrophil, prognostic nutritional index, and their combination.[@b26-cmar-10-6029],[@b42-cmar-10-6029],[@b43-cmar-10-6029] The results of our study suggest that inflammatory components such as lymphocytes, PLT, neutrophils, and WBC play a critical role in the development and progression of CA. The specific relationships between these components and poor survival are yet to be elucidated. However, pretreatment lymphocyte and neutrophil numbers indicate the level of systemic inflammation.[@b44-cmar-10-6029]--[@b46-cmar-10-6029] Inflammation may change the tumor microenvironment and lead to promotion of angiogenesis and metastasis.[@b25-cmar-10-6029],[@b47-cmar-10-6029],[@b48-cmar-10-6029] Moreover, circulating lymphocytes may secrete cytokines that play a role in preventing proliferation and metastatic process and in cytotoxicity. Lower lymphocyte levels and NLR imbalance may promote progression of malignancy. More advanced cancer stage may significantly affect hematological parameters, unlike smaller tumors. Thus, the NLR reflects the balance between inflammatory and immune responses.[@b19-cmar-10-6029],[@b49-cmar-10-6029] Moreover, more advanced FIGO stage (FIGO IIB-IVA) in patients with CA is a poor prognostic factor for OS; in our study, treatment with RT/CCRT was related to a poor prognosis, probably related to the disease severity. However, we have to consider that this is the treatment of choice for this group of patients, and our study aimed to identify inexpensive markers that can be conveniently used for patient identification. Based on the results of the studies available in the literature, and analyzing the relationship between the value of the assessed parameters and the survival of patients, we can conclude that they may have a prognostic value. We also know that the inflammation process may promote the cancer progression. We assume that an unfavorable prognosis of patients with adenocarcinoma of the cervix is not a result of the increased value of the analyzed parameters. Elevated parameters seem to be a symptom of cancer advancement and evidence that a value of coefficients reflects the fact that after exceeding a limit, the tumor mass is so high that the chances for a favorable treatment outcome are drastically reduced. Future studies are necessary to assess additive, alternative, or more effective treatment regimens.

The strength of our study was the large group of patients with CA and the long follow-up, which presented mature results. To our knowledge, this is the first report on the influence of inflammatory parameters on the outcome of patients with CA. The weakness of our study is its retrospective nature and single institution experience. However, if proven in future clinical studies, WBC, NLR, and PLR might be novel, relatively easily available, and inexpensive prognostic markers that help in guiding therapeutic methods and identifying CA patients with high-risk profiles. A histological type, characterized by a poorer prognosis among patients with cervical cancer and concerning an increasingly younger population, our study identified high-risk patients with CA FIGO IIB-- IV and elevated WBC, NLR, and PLR before treatment. If confirmed in larger cohorts, these hematological parameters and ratios may identify patients who may respond to anti-inflammatory treatment.

Conclusion
==========

To our knowledge, this is the largest report of CA patients with mature data. We first demonstrated the prognostic significance of pretreatment PLR, NLR, and WBC values on the survival of patients with CA. Furthermore, the combination of NLR and PLR may enable risk stratification for survival prediction. These parameters can be derived directly from routine blood cell counts, making it an easily available marker for individual risk assessment and stratification of patients with uterine CA, in addition to the clinical stage. Changes in blood NLR and PLR might have utility in tailored therapy, especially in advanced stages that lack reliable markers.
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![Medians and WBC values according to clinical status (alive vs dead).\
**Abbreviation:** WBC, white blood cell count.](cmar-10-6029Fig1){#f1-cmar-10-6029}

![The probability of RFS according to NLR.\
**Notes:** (**A**) RFS of CA patients treated with RT/CCRT stratified by NLR. (**B**) Probability of RFS according to NLR in patients treated with primary surgery and adjuvant RT/CCRT.\
**Abbreviations:** CA, cervical adenocarcinoma; CCRT, chemoradiotherapy; NLR, neutrophil to lymphocyte ratio; RFS, recurrence-free survival; RT, radiotherapy.](cmar-10-6029Fig2){#f2-cmar-10-6029}

![OS of CA patients stratified by NLR.\
**Abbreviations:** CA, cervical adenocarcinoma; NLR, neutrophil to lymphocyte ratio; OS, overall survival.](cmar-10-6029Fig3){#f3-cmar-10-6029}

![The probability of OS according to the PLR in patients with FIGO stage IIB-IV treated with RT/CCRT.\
**Abbreviations:** CCRT, chemoradiotherapy; FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; PLR, platelet to lymphocyte ratio; RT, radiotherapy.](cmar-10-6029Fig4){#f4-cmar-10-6029}

###### 

Patients, treatment, and clinical outcome characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                                                            Feature               Number of patients (%) 94 (100%)
  ---------------------------------------------------------------------------------------------------- --------------------- ----------------------------------
                                                                                                                             

  Age, years                                                                                           Median (range)        53 (20--81)

                                                                                                                             

  MS                                                                                                   Premenopausal         37 (39)

  Postmenopausal                                                                                       57 (61)               

                                                                                                                             

  FIGO stage                                                                                           IA                    2 (2)

  IB                                                                                                   33 (35)               

  IIA                                                                                                  7 (7.5)               

  IIB                                                                                                  24 (25.5)             

  IIIA                                                                                                 0 (0)                 

  IIIB                                                                                                 26 (28)               

  IVA                                                                                                  1 (1)                 

  IVB                                                                                                  1 (1)                 

                                                                                                                             

  AJCC stage                                                                                           T1BN0M0               33 (35)

  T1BN1M0                                                                                              2 (2)                 

  T2N0M0                                                                                               24 (26)               

  T2N1M0                                                                                               7 (7.5)               

  T2N0M1                                                                                               0 (0)                 

  T3N0M0                                                                                               18 (19)               

  T3N1M0                                                                                               7 (7.5)               

  T3N1M1                                                                                               1 (1)                 

  T4N0M0                                                                                               1 (1)                 

  T4N1M0                                                                                               1 (1)                 

                                                                                                                             

  Histology                                                                                            Pure adenocarcinoma   54 (57.5)

  Papillare                                                                                            10 (11)               

  Adenosquamous                                                                                        6 (6)                 

  Mucinous                                                                                             11 (12)               

  Endometrioides                                                                                       4 (4)                 

  Clear cell                                                                                           7 (7.5)               

  Small cell                                                                                           1 (1)                 

  Villoglandular                                                                                       1 (1)                 

                                                                                                                             

  Tumor grade                                                                                          G1                    23 (24.5)

  G2                                                                                                   39 (41.5)             

  G3                                                                                                   12 (13)               

  Gx                                                                                                   20 (21)               

                                                                                                                             

  LN                                                                                                   N+                    18 (19)

  N−                                                                                                   68 (72)               

  ND                                                                                                   8 (9)                 

                                                                                                                             

  Treatment                                                                                            Surgery               7 (7.5)

  Surgery + BT                                                                                         5 (5.3)               

  Surgery + CCRT + BT                                                                                  22 (23.4)             

  Surgery + EBRT + BT                                                                                  13 (13.8)             

  CCRT                                                                                                 45 (48)               

  EBRT                                                                                                 2 (2)                 

                                                                                                                             

  EBRT                                                                                                 46 Gy/23 fr           49 (52)

  45 Gy/25 fr                                                                                          7 (7)                 

  45.9 Gy/27 fr                                                                                        1 (1)                 

  50.4 Gy/28 fr                                                                                        0                     

  50 Gy/25 fr                                                                                          7 (7)                 

  Boost delivered to enlarged lymph nodes over 2 cm in short axis 59.4 Gy/27 fr to 60 Gy/27 fr (SIB)   6 (6)                 

  64 Gy/23 fr + boost delivered to U&P                                                                 4 (4)                 

                                                                                                                             

  BT HDR\                                                                                              30 Gy/4 fr            25 (24)
  BT LDR                                                                                                                     

  22.5 Gy/3 fr                                                                                         7 (7)                 

  15 Gy/2 fr                                                                                           25 (27)               

  28 Gy/4 fr                                                                                           2 (2)                 

  45 Gy/2 fr                                                                                           7 (7)                 

                                                                                                                             

  BT                                                                                                   LDR                   7 (7)

  HDR                                                                                                  59 (63)               

  RSA                                                                                                  40 (43)               

  IT                                                                                                   17(40)                

  FA                                                                                                   22 (50)               

  T&R                                                                                                  4 (10)                

                                                                                                                             

  CHTH (DDP)                                                                                           1--3 courses          5 (11)

  4--6 courses                                                                                         40 (89)               

                                                                                                                             

  Recurrence                                                                                           Yes                   44 (47)

  No                                                                                                   50 (53)               

  Age of recurrence                                                                                    Median (range)        54 (26--85)

                                                                                                                             

  Recurrence\                                                                                          Premenopausal         15 (34)
  AMS                                                                                                                        

  Postmenopausal                                                                                       29 (65)               

                                                                                                                             

  AF                                                                                                   I--IIA                13 (30)

  IIB--IV                                                                                              31 (70)               

                                                                                                                             

  Death                                                                                                Yes                   48 (51)

  No                                                                                                   46 (49)               

  Age of death                                                                                         Median (range)        54 (26--85)

                                                                                                                             

  Death AMS                                                                                            Premenopausal         17 (35)

  Postmenopausal                                                                                       31 (65)               

                                                                                                                             

  Death AF                                                                                             I--IIA                12 (25)

  IIB--IV                                                                                              36 (75)               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AF, according to FIGO; AJCC, American Joint Committee on Cancer; AMS, according to menopausal status; BT, brachytherapy; CCRT, radiochemotherapy; CHTH, chemotherapy; DDP, cisplatin; EBRT, external beam radiation therapy; FA, Fletcher applicator; FIGO, International Federation of Gynecology and Obstetrics; fr, fraction; HDR, high-dose rate; IT, interstitial; LDR, low-dose rate; LN, lymph nodes; MS, menopausal status; ND, no data; RSA, roller-shaped applicator; SIB, simultaneous integrated boost; T&R, tandem and ring; U&P, uterus and parametria.

###### 

Median values and concentration ranges for NLR, PLR, MLR, WBC, Hb, and PLT according to the clinical condition

  Patient groups       NLR                PLR               MLR                 WBC, G/L          Hb, G/dL            PLT, G/L
  -------------------- ------------------ ----------------- ------------------- ----------------- ------------------- ----------------
  All patients         2.32 (0.7--20.3)   158 (62.6--634)   0.31 (0.13--11.2)   6.6 (1.8--18.6)   12.8 (97.7--15.2)   279 (143--831)
  FIGO I--IIA          1.93 (0.7--20.3)   149 (80.8--634)   0.28 (0.13--11.2)   6.1 (3.9--17.7)   12.5 (9.2--14.8)    258 (143--509)
  FIGO IIB--IV         2.7 (1.03--9.6)    160 (62.6--539)   0.33 (0.14--10.2)   6.9 (1.8--18.6)   12.9 (7.7--15.2)    284 (156--831)
  Without recurrence   2.2 (0.8--20.3)    156 (80.8--584)   0.31 (0.13--11.1)   6.1 (1.8--17.7)   12.9 (7.8--15.2)    256 (143--603)
  With recurrence      2.35 (0.7--11.9)   165 (62.6--634)   0.32 (0.14--2.1)    7.1 (3.9--18.6)   12.6 (7.7--15.2)    287 (175--831)
  Died                 2.6 (0.68--11.9)   160 (62.6--634)   0.31 (0.14--0.91)   7.2 (3.9--18.6)   12.7 (7.7--15.2)    286 (175--831)

**Abbreviations:** FIGO, International Federation of Gynecology and Obstetrics; Hb, hemoglobin; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PLT, platelets; WBC, white blood cell count.

###### 

ROC analysis: NLR, PLR, and MLR test characteristics for remission or recurrence in patients with adenocarcinoma of the cervix

  Parameters   Cutoff   Sensitivity   Specificity   AUC
  ------------ -------- ------------- ------------- -------
  NLR          1.6      88.1          31.8          0.562
  PLR          158      57.1          59.1          0.527
  MLR          0.33     45.2          68.2          0.511

**Abbreviations:** AUC, area under the curve; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; ROC, receiver operating characteristic.
